Neuroimaging, cancer, and cognition: State of the knowledge

Seminars in Oncology Nursing

Volumn 29, Issue 4, 2013, Pages 280-287

  Holohan, Kelly N ^a   Von Ah, Diane ^b   McDonald, Brenna C ^a   Saykin, Andrew J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

Cancer; Cognition; Neuroimaging; Review

Indexed keywords

ARTICLE; BRAIN TUMOR; BREAST TUMOR; COGNITION; FEMALE; HUMAN; METASTASIS; NEOPLASM; NEUROIMAGING; PATHOLOGY; REVIEW;

CANCER; COGNITION; NEUROIMAGING; REVIEW;

BRAIN NEOPLASMS; BREAST NEOPLASMS; COGNITION; FEMALE; HUMANS;

EID: 84887137565     PISSN: 07492081     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soncn.2013.08.008     Document Type: Article

References (54)

1. Silk T.J., Wood A.G. Lessons about neurodevelopment from anatomical magnetic resonance imaging. J Dev Behav Pediatr 2011, 32:158-168.
2. Ashburner J., Friston K.J. Voxel-based morphometry-the methods. NeuroImage 2000, 11(6 Pt 1):805-821.
3. Assaf Y., Pasternak O. Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review. J Mol Neurosci 2008, 34:51-61.
4. Basser P.J., Mattiello J., LeBihan D. MR diffusion tensor spectroscopy and imaging. Biophys J 1994, 66:259-267.
5. Lee M.H., Smyser C.D., Shimony J.S. Resting-state fMRI: a review of methods and clinical applications. AJNR Am J Neuroradiol 2012, [Epub ahead of print].
6. Huettel S.A., McCarthy G. Functional magnetic resonanceimaging 2009, Sinauer Associates, Sunderland, MA. Ed2.
7. Christen T., Bolar D.S., Zaharchuk G. Imaging brain oxygenation with MRI using blood oxygenation approaches: methods, validation, and clinical applications. AJNR Am J Neuroradiol 2012, 34:1113-1123.
8. Posse S., Otazo R., Dager S.R., et al. MR spectroscopic imaging: principles and recent advances. J Magn Reson Imaging 2013, 37:1301-1325.
9. Pike V.W. PET radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci 2009, 30:431-440.
10. Silverman D.H., Alavi A. PET imaging in the assessment of normal and impaired cognitive function. Radiol Clin North Am 2005, 43:67-77. x.
11. Silverman D.H., Mosconi L., Ercoli L., et al. Positron emission tomography scans obtained for the evaluation of cognitive dysfunction. Semin Nucl Med 2008, 38:251-261.
12. Butler R.W., Haser J.K. Neurocognitive effects of treatment for childhood cancer. Ment Retard Dev Disabil Res Rev 2006, 12:184-191.
13. Ganz P.A., Bower J.E., Kwan L., et al. Does tumor necrosis factor-alpha (TNF-alpha) play a role in post-chemotherapy cerebral dysfunction?. Brain Behav Immun 2013, 30(suppl):S99-S108.
14. Kesler S., Janelsins M., Koovakkattu D., et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun 2013, 30(suppl):S109-S116.
15. Abraham J., Haut M.W., Moran M.T., et al. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008, 8:88-91.
16. Bergouignan L., Lefranc J.P., Chupin M., et al. Breast cancer affects both the hippocampus volume and the episodic autobiographical memory retrieval. PLoS One 2011, 6:e25349.
17. Bruno J., Hosseini S.M., Kesler S. Altered resting state functional brain network topology in chemotherapy-treated breast cancer survivors. Neurobiol Dis 2012, 48:329-338.
18. Cimprich B., Reuter-Lorenz P., Nelson J., et al. Prechemotherapy alterations in brain function in women with breast cancer. J Clin Exp Neuropsychol 2010, 32:324-331.
19. Conroy S.K., McDonald B.C., Smith D.J., et al. Alterations in brain structure and function in breast cancer survivors: effect of post-chemotherapy interval and relation to oxidative DNA damage. Breast Cancer Res Treat 2013, 137:493-502.
20. de Ruiter M.B., Reneman L., Boogerd W., et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp 2012, 33:2971-2983.
21. de Ruiter M.B., Reneman L., Boogerd W., et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 2011, 32:1206-1219.
22. Deprez S., Amant F., Smeets A., et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol 2012, 30:274-281.
23. Deprez S., Amant F., Yigit R., et al. Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp 2011, 32:480-493.
24. Ferguson R.J., McDonald B.C., Saykin A.J., et al. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. Hum Brain Mapp 2011, 32:480-493.
25. Hosseini S.M., Koovakkattu D., Kesler S.R. Altered small world properties of gray matter networks in breast cancer. BMC Neurol 2012, 12:28.
26. Inagaki M., Yoshikawa E., Matsuoka Y., et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007, 109:146-156.
27. Kesler S.R., Bennett F.C., Mahaffey M.L., et al. Regional brain activation during verbal declarative memory in metastatic breast cancer. Clin Cancer Res 2009, 15:6665-6673.
28. Kesler S.R., Kent J.S., O'Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol 2011, 68:1447-1453.
29. Koppelmans V., de Ruiter M.B., van der Lijn F., et al. Global and focal brain volume in long-term breast cancer survivors exposed to adjuvant chemotherapy. Breast Cancer Res Treat 2012, 132:1099-1106.
30. Koppelmans V., Groot M.D., de Ruiter M.B., et al. Global and focal white matter integrity in breast cancer survivors 20 years after adjuvant chemotherapy. Hum Brain Mapp 2012, [Epub ahead of print].
31. Lopez Zunini R.A., Scherling C., Wallis N., et al. Differences in verbal memory retrieval in breast cancer chemotherapy patients compared to healthy controls: a prospective fMRI study. Brain Imaging Behav 2012, [Epub ahead of print].
32. McDonald B.C., Conroy S.K., Ahles T.A., et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat 2010, 123:819-828.
33. McDonald B.C., Conroy S.K., Ahles T.A., et al. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol 2012, 30:2500-2508.
34. McDonald B.C., Conroy S.K., Smith D.J., et al. Frontal graymatter reduction after breast cancer chemotherapy andassociation with executive symptoms: A aeplication and extension study. Brain Behav Immun 2013, 30(suppl):S117-S125.
35. Reuter-Lorenz P.A., Cimprich B. Cognitive function and breast cancer: promise and potential insights from functional brain imaging. Breast Cancer Res Treat 2013, 137:33-43.
36. Scherling C., Collins B., Mackenzie J., et al. Pre-chemotherapy differences in visuospatial working memory in breast cancer patients compared to controls: an FMRI study. Front Hum Neurosci 2011, 5:122.
37. Scherling C., Collins B., Mackenzie J., et al. Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: a functional magnetic resonance imaging study. J Clin Exp Neuropsychol 2012, 34:543-560.
38. Silverman D.H., Dy C.J., Castellon S.A., et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007, 103:303-311.
39. Yoshikawa E., Matsuoka Y., Inagaki M., et al. No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 2005, 92:81-84.
40. Saykin A.J., Ahles T.A., McDonald B.C. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 2003, 8:201-216.
41. Kumano H., Ida I., Oshima A., et al. Brain metabolic changes associated with predispotion to onset of major depressive disorder and adjustment disorder in cancer patients-a preliminary PET study. J Psychiatr Res 2007, 41:591-599.
42. Tashiro M., Itoh M., Kubota K., et al. Relationship between trait anxiety, brain activity and natural killer cell activity in cancer patients: a preliminary PET study. Psychooncology 2001, 10:541-546.
43. Tashiro M., Juengling F.D., Moser E., et al. High social desirability and prefrontal cortical activity in cancer patients: a preliminary study. Med Sci Monit 2003, 9:CR119-CR124.
44. Tashiro M., Juengling F.D., Reinhardt M.J., et al. Reproducibility of PET brain mapping of cancer patients. Psychooncology 2000, 9:157-163.
45. Tashiro M., Juengling F.D., Reinhardt M.J., et al. Depressive state and regional cerebral activity in cancer patients - a preliminary study. Med Sci Monit 2001, 7:687-695.
46. Tashiro M., Kubota K., Itoh M., et al. Hypometabolism in the limbic system of cancer patients observed by positron emission tomography. Psychooncology 1999, 8:283-286.
47. Golan H., Kennedy J.A., Frenkel A., et al. Brain mappingofpatients with lung cancer and controls: inquiryinto tumor-to-brain communication. J Nucl Med 2009, 50:1072-1075.
48. Benveniste H., Zhang S., Reinsel R.A., et al. Brain metabolomic profiles of lung cancer patients prior to treatment characterized by proton magnetic resonance spectroscopy. Int J Clin Exp Med 2012, 5:154-164.
49. Deprez S., Billiet T., Sunaert S., et al. Diffusion tensor MRI of chemotherapy-induced cognitive impairment in non-CNS cancer patients: a review. Brain Imaging Behav 2013, [Epub ahead of print].
50. McDonald B.C., Saykin A.J. Neurocognitive dimensions of breast cancer and its treatment. Neuropsychopharmacology 2011, 36:355-356.
51. Silverman D., Castellon S.A., Abraham L., et al. Abnormal regional brain metabolism in breast cancer survivors after adjuvant chemotherapy is associated with cognitive changes [abstr 47]. Proc Am Soc Clin Oncol 2003, 22.
52. Saykin A., Ahles T.A., Schoenfeld J.D., et al. Gray matter reduction on voxel-based morphometry in chemotherapy-treated cancer survivors. J Int Neuropsychol Soc 2003, 9(246). [abstract].
53. Hermelink K., Kuchenhoff H., Untch M., et al. Two different sides of 'chemobrain': determinants and nondeterminants of self-perceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology 2010, 19):1321-1328.
54. Von Ah D., Habermann B., Carpenter J.S., et al. Impact of perceived cognitive impairment in breast cancer survivors. Eur J Oncol Nurs 2013, 17:236-241.